Pregabalin Capsule
Product Images NDC 71335-9699

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-9699). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713359699)

Pregabalin Capsules 200 mg label by Bryant Ranch Prepack. The label states each capsule contains 200 mg Pregabalin. The package contains 30 capsules for oral use. Storage instructions indicate to keep at 25°C (77°F) with excursions permitted from 15° to 30°C (59° to 86°F). The product is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by ScieGen Pharmaceuticals, Inc. The label includes the NDC 71335-9699-1 and a barcode.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, illustrating different levels of patient improvement at various percentages of pain reduction.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg taken three times a day and placebo. The vertical axis represents the percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline, ranging from 0 to 100%.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing percent of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. It compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and placebo, illustrating differences in patient improvement percentages over various pain improvement thresholds.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing the percent of patients improved by levels of percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The vertical axis shows percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph comparing percent improvement in pain from baseline versus percent of patients improved for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows trends of pain improvement among these three study groups.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) across different dosages of Pregabalin and placebo in two clinical studies labeled E1 and E3. The x-axis shows dosage groups with sample sizes, and the y-axis shows responder rate percentages. Bars indicate higher responder rates with increasing Pregabalin doses compared to placebo, with statistical significance noted.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line chart depicting seizure reduction as median percent change from baseline on the y-axis versus dose in mg/day on the x-axis. The chart compares data from four studies (E1 BD, E2 TID, E3 BD, E3 TID) using different markers and shows statistically significant p-values at various dose points, indicating differences in seizure reduction efficacy for pregabalin doses up to 600 mg/day.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph plotting percent improvement in pain from baseline on the x-axis against percent of patients improved on the y-axis. The graph compares four lines representing Pregabalin dosages of 300 mg, 450 mg, and 800 mg daily doses, and placebo, showing the relationship between increasing pain improvement and patient response rates for each dose group.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A survival curve graph comparing Pregabalin versus placebo over 180 days. The Y-axis shows the estimated percentage of subjects without LTR, and the X-axis shows time in days. Two lines represent the treatment groups: a solid line for Pregabalin and a dashed line for placebo, indicating differences in outcomes over time.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to week 12 between Pregabalin and placebo groups. The x-axis shows percent improved from baseline to week 12 BOCF, ranging from 0 to 100. The y-axis shows percent of subjects improved, ranging from 0 to 100. Solid line represents Pregabalin and dotted line represents placebo, with Pregabalin showing higher percentages of subjects improved across the range.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved over a range of percent improvement from baseline to week 16 for Pregabalin capsules 200 mg versus placebo. The x-axis represents percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved. Two lines are shown, one solid for Pregabalin and one dashed for placebo, illustrating greater improvement in subjects taking Pregabalin compared to placebo.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A pharmacokinetic or dosing formula showing creatinine clearance (CLcr) calculation based on age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor for female patients (0.85). This formula is often used to estimate kidney function.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin, the active ingredient in the product Pregabalin 200 mg capsules by Bryant Ranch Prepack. The structure shows the molecular arrangement of the compound with key functional groups including an amino group and a carboxylic acid group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.